Skip to content

2026 · Under review at Briefings in Bioinformatics

Disease-level drug approval forecasting from trial-agnostic public data

Samir Townsley, Pagkratios Tagkopoulos, Ilias Tagkopoulos

    Summary

    The paper forecasts drug approvals at the level of a disease rather than a single clinical trial, using only public data that does not depend on the details of any one trial.